No buyer found: three Biontech plants shut down

TVS News AI, editorially supervised, presents No buyer found: three Biontech plants shut down.

During the Covid pandemic, Biontech was the ultimate winner: billions in revenue from a vaccine that was in demand worldwide.

But those times are over. The pharmaceutical company is under massive cost-cutting pressure – and three sites are now feeling this particularly acutely.

According to matching reports from Handelsblatt and Zeit, it's clear: no buyer was found for three Biontech plants. The plants are being shut down.

During the Covid pandemic, Biontech earned billions – that's over. The company must save, is cutting staff. Now it's clear that at three sites the gates are closing for good.

What does this mean for Biontech?

Biontech shows how quickly a pandemic boom can fade. Back then, the money was rolling in; now the company must cut costs in the face of plunging revenues, reduce staff and shed sites. The fact that no investor was found even for three of them doesn't make the situation any easier – the cost-cutting program thus goes directly into the next round.

What does this mean for employees?

The plant closures are part of the ongoing staff reductions at Biontech. Employees at the three affected sites must prepare for the loss of their jobs – as a direct result of the end of the pandemic-driven special boom.

As of: September 28, 2026, based on reports from Handelsblatt and Zeit.